{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:44:08Z","timestamp":1785800648613,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Pediatric Neuro-Oncology Research Fund at Riley in Honor of Cecilia Bea Crockett"},{"name":"National Institute of Health NINDS Career Development Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Molecular testing has become a cornerstone in pediatric neuro-oncology but relies on time intensive workflows at specialized centers. We hypothesized that time to adjuvant therapy has increased since the incorporation of molecular testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective case series, data were collected from Riley Hospital for Children in Indianapolis from the pre-molecular era (2007\u20132009) and the molecular era (2023\u20132025). Patients aged\u2009\u2264\u200921 years who received initial surgery for a primary brain tumor were included. The primary outcome of interest was the time from initial surgery to initiation of adjuvant treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 140 patients met inclusion criteria, including 83 who received adjuvant therapy as part of the initial postoperative treatment plan. Time to adjuvant treatment was significantly shorter in the pre-molecular cohort (24.5 vs 34.2 days). Multivariate analysis demonstrated that this prolonged time to treatment was associated with the use of targeted therapies that rely on molecular testing for diagnosis, and increased patient referrals to external institutions during the molecular era. The most cited reasons for delay in adjuvant treatment were final pathology report pending, family decision making, and shunt-related factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Time to adjuvant therapy was longer in the molecular era, and this effect was attributable to evolving treatment paradigms, specifically the adoption of targeted therapies related to molecular diagnosis and increased reliance on external treatment centers. These results underscore modifiable, system-level barriers in the delivery of precision oncology which represent key opportunities to improve timeliness of care and, ultimately, patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00381-026-07419-1","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:50:09Z","timestamp":1785797409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time to adjuvant treatment for newly diagnosed pediatric brain tumors in the molecular era: a single center retrospective study"],"prefix":"10.1007","volume":"42","author":[{"given":"Kenneth L.","family":"Virgin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinan","family":"Ayub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie L.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8137-7202","authenticated-orcid":false,"given":"Jignesh K.","family":"Tailor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"1","key":"7419_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/ije\/dyl272","volume":"36","author":"V Wunderlich","year":"2007","unstructured":"Wunderlich V (2007) Early references to the mutational origin of cancer. Int J Epidemiol 36(1):246\u2013247. https:\/\/doi.org\/10.1093\/ije\/dyl272","journal-title":"Int J Epidemiol"},{"issue":"4","key":"7419_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","volume":"123","author":"MD Taylor","year":"2012","unstructured":"Taylor MD, Northcott PA, Korshunov A et al (Apr2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465\u2013472. https:\/\/doi.org\/10.1007\/s00401-011-0922-z","journal-title":"Acta Neuropathol"},{"issue":"6","key":"7419_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"issue":"1","key":"7419_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/neuonc\/noaf250","volume":"28","author":"KS Smith","year":"2026","unstructured":"Smith KS, Dhanda SK, Billups CA et al (2026) An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival. Neuro Oncol 28(1):268\u2013281. https:\/\/doi.org\/10.1093\/neuonc\/noaf250","journal-title":"Neuro Oncol"},{"key":"7419_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2026.101076","author":"H Liu","year":"2026","unstructured":"Liu H, Su Y, Zhang J et al (2026) Long-term outcomes by clinical and molecular risk stratification in patients with medulloblastoma receiving risk-adapted therapy. Med. https:\/\/doi.org\/10.1016\/j.medj.2026.101076","journal-title":"Med"},{"key":"7419_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2025.101186","volume":"53","author":"K Parikh","year":"2025","unstructured":"Parikh K, Sait SF (2025) Pediatric CNS tumors: overview and treatment paradigms. Semin Pediatr Neurol 53:101186. https:\/\/doi.org\/10.1016\/j.spen.2025.101186","journal-title":"Semin Pediatr Neurol"},{"key":"7419_CR7","doi-asserted-by":"publisher","unstructured":"Rajappa P, Eng KW, Bareja R, et al. Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors. Neurooncol Adv. Jan\u2013Dec 2022;4(1):vdac031. https:\/\/doi.org\/10.1093\/noajnl\/vdac031","DOI":"10.1093\/noajnl\/vdac031"},{"issue":"12","key":"7419_CR8","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML et al (2023) Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389(12):1108\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa2303815","journal-title":"N Engl J Med"},{"issue":"24","key":"7419_CR9","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.Ccr-19-2177","volume":"25","author":"DR Hargrave","year":"2019","unstructured":"Hargrave DR, Bouffet E, Tabori U et al (2019) Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study. Clin Cancer Res 25(24):7303\u20137311. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2177","journal-title":"Clin Cancer Res"},{"issue":"7586","key":"7419_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature16478","volume":"529","author":"AS Morrissy","year":"2016","unstructured":"Morrissy AS, Garzia L, Shih DJ et al (2016) Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529(7586):351\u2013357. https:\/\/doi.org\/10.1038\/nature16478","journal-title":"Nature"},{"issue":"7","key":"7419_CR11","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.cell.2020.10.044","volume":"183","author":"F Petralia","year":"2020","unstructured":"Petralia F, Tignor N, Reva B et al (2020) Integrated proteogenomic characterization across major histological types of pediatric brain cancer. Cell 183(7):1962-1985.e31. https:\/\/doi.org\/10.1016\/j.cell.2020.10.044","journal-title":"Cell"},{"issue":"7386","key":"7419_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10825","volume":"482","author":"X Wu","year":"2012","unstructured":"Wu X, Northcott PA, Dubuc A et al (2012) Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482(7386):529\u2013533. https:\/\/doi.org\/10.1038\/nature10825","journal-title":"Nature"},{"issue":"1","key":"7419_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51276-y","volume":"15","author":"F Chen","year":"2024","unstructured":"Chen F, Zhang Y, Shen L, Creighton CJ (2024) The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival. Nat Commun 15(1):6775. https:\/\/doi.org\/10.1038\/s41467-024-51276-y","journal-title":"Nat Commun"},{"issue":"2","key":"7419_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s2352-4642(19)30342-6","volume":"4","author":"JC Pickles","year":"2020","unstructured":"Pickles JC, Fairchild AR, Stone TJ et al (2020) DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. Lancet Child Adolesc Health 4(2):121\u2013130. https:\/\/doi.org\/10.1016\/s2352-4642(19)30342-6","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"7419_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12838","volume":"48","author":"E Schepke","year":"2022","unstructured":"Schepke E, L\u00f6fgren M, Pietsch T et al (2022) DNA methylation profiling improves routine diagnosis of paediatric central nervous system tumours: a prospective population-based study. Neuropathol Appl Neurobiol 48(6):e12838. https:\/\/doi.org\/10.1111\/nan.12838","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"12","key":"7419_CR16","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jamaoncol.2016.2547","volume":"2","author":"BH Kann","year":"2016","unstructured":"Kann BH, Park HS, Lester-Coll NH et al (2016) Postoperative radiotherapy patterns of care and survival implications for medulloblastoma in young children. JAMA Oncol 2(12):1574\u20131581. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2547","journal-title":"JAMA Oncol"},{"issue":"17","key":"7419_CR17","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1002\/cncr.25988","volume":"117","author":"A Ishkanian","year":"2011","unstructured":"Ishkanian A, Laperriere NJ, Xu W et al (2011) Upfront observation versus radiation for adult pilocytic astrocytoma. Cancer 117(17):4070\u20134079. https:\/\/doi.org\/10.1002\/cncr.25988","journal-title":"Cancer"},{"issue":"Supplement_4","key":"7419_CR18","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","volume":"27","author":"M Price","year":"2025","unstructured":"Price M, Ballard CAP, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT (2025) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022. Neuro Oncol 27(Supplement_4):iv1\u2013iv66. https:\/\/doi.org\/10.1093\/neuonc\/noaf194","journal-title":"Neuro Oncol"},{"issue":"6","key":"7419_CR19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3171\/2017.6.Peds17117","volume":"20","author":"S Chotai","year":"2017","unstructured":"Chotai S, Guidry BS, Chan EW et al (2017) Unplanned readmission within 90 days after pediatric neurosurgery. J Neurosurg Pediatr 20(6):542\u2013548. https:\/\/doi.org\/10.3171\/2017.6.Peds17117","journal-title":"J Neurosurg Pediatr"},{"issue":"26","key":"7419_CR20","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMp1802313","volume":"378","author":"AJH Kind","year":"2018","unstructured":"Kind AJH, Buckingham WR (2018) Making neighborhood-disadvantage metrics accessible - the neighborhood atlas. N Engl J Med 378(26):2456\u20132458. https:\/\/doi.org\/10.1056\/NEJMp1802313","journal-title":"N Engl J Med"},{"issue":"9","key":"7419_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00953-4","volume":"22","author":"L Szalontay","year":"2020","unstructured":"Szalontay L, Khakoo Y (2020) Medulloblastoma: an old diagnosis with new promises. Curr Oncol Rep 22(9):90. https:\/\/doi.org\/10.1007\/s11912-020-00953-4","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"7419_CR22","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.6004\/jnccn.2023.7024","volume":"21","author":"A Bagchi","year":"2023","unstructured":"Bagchi A, Dhanda SK, Dunphy P, Sioson E, Robinson GW (2023) Molecular classification improves therapeutic options for infants and young children with medulloblastoma. J Natl Compr Canc Netw 21(10):1097\u20131105. https:\/\/doi.org\/10.6004\/jnccn.2023.7024","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"7419_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/08880018.2021.1907493","volume":"38","author":"J Pearce","year":"2021","unstructured":"Pearce J, Khabra K, Nanji H et al (Nov2021) High grade gliomas in young children: the South Thames Neuro-Oncology unit experience and recent advances in molecular biology and targeted therapies. Pediatr Hematol Oncol 38(8):707\u2013721. https:\/\/doi.org\/10.1080\/08880018.2021.1907493","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"7419_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf086","volume":"7","author":"RY Diaz-Coronado","year":"2025","unstructured":"Diaz-Coronado RY, Alcasabas APA, Baticulon RE et al (2025) Outcomes of pediatric medulloblastoma in low- and middle-income countries: a retrospective analysis of 335 cases from 8 countries. Neuro-Oncol Adv 7(1):vdaf086. https:\/\/doi.org\/10.1093\/noajnl\/vdaf086","journal-title":"Neuro-Oncol Adv"},{"issue":"1","key":"7419_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271778","volume":"18","author":"T Jaruthien","year":"2023","unstructured":"Jaruthien T, Nantavithya C, Santisukwongchote S et al (2023) Postoperative radiotherapy timing, molecular subgroups and treatment outcomes of Thai pediatric patients with medulloblastoma. PLoS ONE 18(1):e0271778. https:\/\/doi.org\/10.1371\/journal.pone.0271778","journal-title":"PLoS ONE"},{"issue":"4","key":"7419_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/archsurg.133.4.383","volume":"133","author":"SO Hofer","year":"1998","unstructured":"Hofer SO, Shrayer D, Reichner JS, Hoekstra HJ, Wanebo HJ (Apr1998) Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg 133(4):383\u2013389. https:\/\/doi.org\/10.1001\/archsurg.133.4.383","journal-title":"Arch Surg"},{"issue":"1","key":"7419_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G et al (2021) Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 6(1):263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"7419_CR28","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s12094-019-02101-2","volume":"21","author":"T de Rojas","year":"2019","unstructured":"de Rojas T, Puertas M, Bautista F et al (2019) Improving the quality of care in the molecular era for children and adolescents with medulloblastoma. Clin Transl Oncol 21(12):1687\u20131698. https:\/\/doi.org\/10.1007\/s12094-019-02101-2","journal-title":"Clin Transl Oncol"},{"key":"7419_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17243982","author":"V Podder","year":"2025","unstructured":"Podder V, Sarfraz Z, Qidwai KA et al (2025) Gaps in diagnosis, treatment, and outcomes among patients with brain tumors in the United States: a state-of-the-art review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17243982","journal-title":"Cancers (Basel)"},{"key":"7419_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.wneu.2024.06.163","volume":"189","author":"SR Sheikh","year":"2024","unstructured":"Sheikh SR, Patel NJ, Recinos VMR (2024) Safety and technical efficacy of pediatric brainstem biopsies: an updated meta-analysis of 1000+ children. World Neurosurg 189:428-438.e2. https:\/\/doi.org\/10.1016\/j.wneu.2024.06.163","journal-title":"World Neurosurg"},{"issue":"6","key":"7419_CR31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1542\/hpeds.2020-004044","volume":"11","author":"CM Brown","year":"2021","unstructured":"Brown CM, Williams DJ, Hall M et al (2021) Trends in length of stay and readmissions in children\u2019s hospitals. Hosp Pediatr 11(6):554\u2013562. https:\/\/doi.org\/10.1542\/hpeds.2020-004044","journal-title":"Hosp Pediatr"},{"issue":"8","key":"7419_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/pec.0000000000002943","volume":"39","author":"AL Young","year":"2023","unstructured":"Young AL, Monuteaux MC, Cooney TM, Michelson KA (2023) Predictors of delayed diagnosis of pediatric CNS tumors in the emergency department. Pediatr Emerg Care 39(8):617\u2013622. https:\/\/doi.org\/10.1097\/pec.0000000000002943","journal-title":"Pediatr Emerg Care"},{"issue":"6","key":"7419_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3171\/2024.12.Peds24394","volume":"35","author":"WA Lambert","year":"2025","unstructured":"Lambert WA, Alexander M, Ayers J et al (2025) Demographic and social determinants of the interval from symptom onset to diagnosis of pediatric brain tumors: a study of the Connecticut Tumor Registry. J Neurosurg Pediatr 35(6):612\u2013620. https:\/\/doi.org\/10.3171\/2024.12.Peds24394","journal-title":"J Neurosurg Pediatr"},{"issue":"2","key":"7419_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.pec.2010.05.021","volume":"83","author":"TE Power","year":"2011","unstructured":"Power TE, Swartzman LC, Robinson JW (2011) Cognitive-emotional decision making (CEDM): a framework of patient medical decision making. Patient Educ Couns 83(2):163\u2013169. https:\/\/doi.org\/10.1016\/j.pec.2010.05.021","journal-title":"Patient Educ Couns"},{"issue":"5","key":"7419_CR35","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1073\/pnas.1215687110","volume":"110","author":"LS Eberlin","year":"2013","unstructured":"Eberlin LS, Norton I, Orringer D et al (2013) Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci U S A 110(5):1611\u20131616. https:\/\/doi.org\/10.1073\/pnas.1215687110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7419_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jmsacl.2025.10.002","volume":"38","author":"M Shahi","year":"2025","unstructured":"Shahi M, Cooks RG (2025) Ambient ionization mass spectrometry in brain cancer diagnosis. J Mass Spectrom Adv Clin Lab 38:37\u201349. https:\/\/doi.org\/10.1016\/j.jmsacl.2025.10.002","journal-title":"J Mass Spectrom Adv Clin Lab"},{"issue":"1","key":"7419_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77044-y","volume":"14","author":"M Shahi","year":"2024","unstructured":"Shahi M, Pringle S, Morris M, Garcia DM, Qui\u00f1ones-Hinojosa A, Cooks RG (2024) Detection of IDH mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry. Sci Rep 14(1):26865. https:\/\/doi.org\/10.1038\/s41598-024-77044-y","journal-title":"Sci Rep"},{"issue":"4","key":"7419_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/jrs.6302","volume":"53","author":"X Tian","year":"2022","unstructured":"Tian X, Chen C, Chen C et al (2022) Application of Raman spectroscopy technology based on deep learning algorithm in the rapid diagnosis of glioma. J Raman Spectrosc 53(4):735\u2013745. https:\/\/doi.org\/10.1002\/jrs.6302","journal-title":"J Raman Spectrosc"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-026-07419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-026-07419-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-026-07419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:50:10Z","timestamp":1785797410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-026-07419-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7419"],"URL":"https:\/\/doi.org\/10.1007\/s00381-026-07419-1","relation":{},"ISSN":["1433-0350"],"issn-type":[{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Financial interests: Kenneth L. Virgin and Jignesh K. Tailor received funding from The Pediatric Neuro-Oncology Research Fund at Riley in Honor of Cecilia Bea Crockett. Jignesh Tailor is funded by the National Institute of Health NINDS Career Development Award. All other authors declare they have no financial interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"322"}}